Pathogenesis, clinical manifestation, and diagnosis of hepatic encephalopathy

Seminars in Liver Disease

Volumn 27, Issue SUPPL. 2, 2007, Pages 3-9

  Mullen, Kevin D ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Ammonia; Diagnosis; Hepatic encephalopathy; Minimal hepatic encephalopathy; Pathogenesis

Indexed keywords

AMMONIA; NEUROTOXIN;

AMMONIA BLOOD LEVEL; ASTROCYTE; BRAIN EDEMA; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; HEPATIC ENCEPHALOPATHY; HUMAN; INFLAMMATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; REVIEW; RISK FACTOR;

EID: 34548174883     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984573     Document Type: Review

References (27)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721
2. Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1): 11-16
3. Cordoba J, Alonso J, Rovira A, et al. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001;35:598-604
4. Haussinger D, Kircheis G, Fischer R, Schliess F, von Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000;32:1035-1038
5. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247-254
6. Schliess F, Görg B, Reinehr R, Bidmon H, Häussinger D. Osmotic and oxidative stress in hepatic encephalopathy. In: Häussinger D, Kirchles G, Schless F, eds. Hepatic Encephalopathy and Nitrogen Metabolism. Dordrecht, The Netherlands: Springer; 2006:20-42
7. Zieve L, Ferenci P, Rzepczynski D, Ebner J, Zimmermann C. A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding. Metab Brain Dis 1987;2:201-205
8. Norenberg MD, Itzhak Y, Bender AS. The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. Adv Exp Med Biol 1997;420:95-111
9. Bender AS, Norenberg MD. Effect of benzodiazepines and neurosteroids on ammonia-induced swelling in cultured astrocytes. J Neurosci Res 1998;54:673-680
10. Jayakumar AR, Rama Rao KV, Kalaiselvi P, Norenberg MD. Combined effects of ammonia and manganese on astrocytes in culture. Neurochem Res 2004;29:2051-2056
11. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005;62:2295-2304
12. Häussinger D, Córdoba J, Kircheis G, et al. Definition and assessment of low-grade hepatic encephalopathy. In: Haussinger D, Kirchels G, Schless F, eds. Hepatic Encephalopathy and Nitrogen Metabolism. Dordrecht, The Netherlands: Springer; 2006:423-432
13. Krieger S, Jauss M, Jansen O, Theilmann L, Geissler M, Krieger D. Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. Gastroenterology 1996;111:147-155
14. Mullen KD, Cole M, Foley JM. Neurological deficits in "awake" cirrhotic patients on hepatic encephalopathy treatment: missed metabolic or metal disorder? Gastroenterology 1996;111:256-257
15. Adams RD, Foley JM. The neurological disorder associated with liver disease. Res Publ Assoc Res Nerv Ment Dis 1953;32:198-237
16. McDermott WV Jr, Adams RD, Riddell AG. Ammonia metabolism in man. Ann Surg 1954;140:539-556
17. Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 1989;96:240-243
18. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16:37-41
19. Morgan MY. Cerebral magnetic resonance imaging in patients with chronic liver disease. Metab Brain Dis 1998; 13:273-290
20. Conn HO. Quantifying the severity of hepatic encephalopathy. In: Conn HO, Bircher J, eds. Hepatic Encephalopathy: Syndromes and Therapies. Bloomington, IL: Medi-ed Press; 1994:13-26
21. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998;28:45-49
22. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45: 549-559
23. Lockwood AH. Clinical and laboratory features of hepatic encephalopathy. In: Hepatic Encephalopathy. Boston: Butterworth-Heinemann; 1992:2-31
24. Bajaj JS, Saeian K, Verber MD, et al. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol 2007;102:754-760
25. Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003;114:188-193
26. Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol 2003;38:441-446
27. Kramer L, Tribl B, Gendo A, et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000;31:30-34